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Abstract
Introduction
Fear of cancer progression (FCP) impacts quality of life, and is a prevalent unmet need in
patients diagnosed with advanced cancer, yet we understand little about its trajectory across
time, particularly as treatment options are reduced. We aimed to identify FCP trajectories
over six months in patients with diverse advanced cancer diagnoses receiving comprehensive
tumour genomic profiling (CTGP) results, and their correlates.
Method
Patients with pathologically confirmed metastatic disease receiving or post their last line of
standard therapy completed questionnaires at T0 ( prior to CTGP), T1 (immediately post
CTGP results) and T2 (2 months later).
Results
High stable (n=52; 7.3%) and low/moderate stable (n=56; 7.8%) FCP trajectories over time
typified the largest groups of participants (N=721). Those with higher FCP (B = 0.61, t(399) =
14.12, p <.001), and lower FACIT-Sp (B = -0.12, t(399) = -2.78, p =.006) at T0, had higher
FCP at T1. Those with a variant that was actionable within a MoST clinical trial, compared to
having a non-actionable variant (B = -1.79, t(399) = -2.01), p =.045) had lower FCP at T1. No
variable predicted change in FCP from T1 to T2.
Discussion
Routine screening for psychological/spiritual characteristics in those about to undergo CTGP
may be helpful in identifying patients who may benefit from closer monitoring and provision
of psychosocial support. Future studies should explore interventions to best address FCP in
this vulnerable group, as interventions assessed to date have almost all addressed patients
with curative cancers or newly diagnosed advanced disease.
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BACKGROUND
Fear of cancer recurrence (FCR) or progression (FCP), defined as “fear, worry or concern
relating to the possibility that cancer will come back or progress,”1 is one of the most
common and distressing concerns after a cancer diagnosis, for which patients often seek
help.2 While research on FCR/P has recently expanded, the literature has primarily focused
on FCR in curatively treated cancers. FCP in the context of advanced cancer is poorly
understood.

FCP is closely associated with the existential distress experienced by patients with incurable
disease.3 Patients with high FCP experience frequent intrusive thoughts about cancer that are
difficult to control, believe strongly that the cancer will progress, describe more elaborate
death-related thoughts, and feel alone in their experience.4-6 A sense that life is meaningful
and purposeful despite the cancer, is proposed to be protective against FCP.3

High FCR/P is associated with increased or decreased screening and health prevention
behaviours due to coping by avoidance or reassurance-seeking,7 negatively impacts emotions,
relationships, work, goal setting, and quality of life,8 and increases health care costs.7 It is
important to understand the causes, trajectory and outcomes of FCP so that those at risk can
be identified early, and given appropriate services.

Data on the prevalence of FCP is scarce. Of 118 women with gynaecological cancers of
mixed stages,9 50% had high FCP that persisted over time. Similarly, between 44% and 56%
of 962 cancer survivors, of whom 200 had metastatic disease, reported high FCP, with most
remaining at that level over the 18-month follow-up period.10 Diverse factors have been
associated with FCR and FCP, including younger age and female gender,11 anxiety,
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depression and stress symptoms12 and intrusions, death anxiety, threat appraisal and metacognitions.3

Longitudinal studies to date13-21 have focused on curative or mixed stage cancers with data
not reported separately for advanced cancer patients. No studies to date have examined FCP
trajectories in patients receiving comprehensive tumour genomic profiling (CTGP), where
patients may experience uncertainty as they wait for results, or receive results which may
dash hope for personalised treatments after standard treatments have failed. Even if positive
results are obtained, uncertainty regarding long-term outcomes from relatively new
treatments may maintain high FCP.

We aimed to identify FCP trajectories over six months in patients with advanced cancer
undergoing CTGP, and their correlates. The study was guided by Protection Motivation
Theory,22 which posits that people defend ourselves according to the perceived: severity and
probability (vulnerability) of danger, effectiveness of protective behaviour, and self-efficacy
in executing the protective behaviour. We hypothesised that:
1. A substantial proportion of patients would have high FCP maintained over time.
2. FCP would be higher and more sustained in younger participants, women, and those
with higher perceived susceptibility to cancer progression, more negative attitudes to
uncertainty, lower self-efficacy in coping with results and lower spiritual wellbeing.
3. FCP would be higher in those with poor knowledge of CTGP, as FCP can lead to
avoidance,7 including of information.

METHODS
Participants and study design
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Participants were recruited from the Molecular Screening and Therapeutics (MoST) study23
from 2016 to 2019. The MoST study recruits adults with pathologically confirmed metastatic
solid cancers of any histological type (70% have rare cancers), receiving or post their last line
of standard therapy, via their oncologists. Eligibility criteria include an Eastern Cooperative
Oncology Group Performance Status of 0 to 3 and sufficient accessible tissue for CTGP. A
CTGP report linking molecular targets with potential therapeutics is issued approximately 11
weeks post consent.
The Psychosocial Issues in Genomics Oncology (PiGeOn) Project is a longitudinal,
mixed methods psychosocial sub-study of the MoST study.24 Participants complete
questionnaires (paper-and-pen or online) at baseline prior to testing (T0), 1 to 4 weeks after
receiving CTGP results (T1), and 5 months after baseline (T2). The current paper reports
longitudinal results related to FCP.

Human ethics approval was obtained from Human Research Ethics Committees at St
Vincent’s Hospital, Sydney, Australia (HREC/16/SVH/23).

Measures
We used psychometrically validated scales where available and study-developed questions if
published scales were inappropriate for our cohort.
At baseline (T0), the following measures were assessed:
Demographics/Cancer variables: including gender, age, education, occupation, language
spoken at home, postcode to determine socio-economic status and remoteness (using the
Accessibility and Remoteness Index of Australia - ARIA), marital and parental status,
personal and family history of cancer, multiple primary cancers diagnosis, previous
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attendance at a family cancer clinic, time since cancer diagnosis and cancer incidence
(common or rare - <6 cases/100,000 population).
FCP: The three-item Concerns about Recurrence Questionnaire (CARQ),25 adapted to
measure FCP e.g. “How emotionally upset or distressed have you been about your cancer
progressing?”. Scores range from 0-30; higher scores indicate greater FCP.
Attitudes towards Uncertainty (in CTGP): Higher scores on this seven-item scale26 (mean
score possible range=1-5) reflect a negative attitude towards uncertainty.
Perceived susceptibility (to cancer progression): One question used a visual analogue scale
ranging from 0-100%.27
Self-efficacy (in coping with CTGP outcomes): Study-adapted questions based on Rosenberg
et al. (2013)28 rated on a 5-point Likert scale; high scores indicated greater self-efficacy.
Knowledge of genomics: Eight study-developed questions assessed, e.g., purposes of CTGP
and its ability to predict cancer risk and guide treatment. Percent of correct responses was
calculated (score 0-100%).
Spiritual wellbeing: The Functional Assessment of Chronic Illness Therapy – Spiritual
Wellbeing (FACIT-Sp-12)29 is comprised of three subscales: peace, meaning and faith.
Scores range from 0-48; higher scores indicate greater spiritual wellbeing.

CTGP Result type
The CTGP result received was classified as: Non-actionable, Actionable: Recommended
treatment via MoST sub-study, or Actionable: Recommended treatment via another pathway.

Immediately post result disclosure (T1), the following were assessed:
FCP: The CARQ,25 as assessed at T0.
Spiritual wellbeing: The FACIT-Sp-1229 as assessed at T0.
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Coping with CTGP results: The 25-item Multidimensional Impact of Cancer Risk
Assessment (MICRA)30 has three subscales: uncertainty, positive experience and distress.
High scores (possible range 0-95) indicate greater distress.
CTGP-related anxiety: The 15-item Impact of Events Scale (IES)31 has two subscales:
intrusive thinking and avoidance. High scores (range 0-69) indicate greater anxiety about
CTGP.
Anxiety and depression: The 14-item Hospital Anxiety and Depression Scale (HADS)32
comprises two sub-scales measuring anxiety and depression. High scores (range 0-75)
indicate greater morbidity.
Hope: The 12-item Herth Hope Index (HHI)33 has three subscales: temporality and future,
positive readiness and expectancy, and inter-connectedness. Score range 12-48; high scores
indicate greater hope.

Statistical analyses
As the CAR-Q lacks published cut-off scores in an advanced cancer population, a median split
on FCP (FCP0=18) was applied to categorize participants as having high (≥18) vs.
low/moderate (<18) FCP at baseline. Change in FCP between T0 to T1 and between T1 to T2
was calculated. FCP change scores of half a standard deviation (0.5*SDFCP0=4) were classified
as clinically significant increases or decreases. Change scores falling in between -4 and +4
were defined as stable FCP.

To test whether change in FCP over time is dependent on the result type, trajectories were split
into two time periods (T0 to T1 and T1 to T2) and collapsed into four clinically meaningful
trajectories. Chi-square tests were applied to test the dependency between Result Type and the
trajectories.
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Two multiple linear regressions were performed to predict (1) FCP at T1 and (2) change in
FCP from T1 to T2 while, in both regressions, controlling for FCP values at T0. Demographics
(e.g. age, sex), clinical variables (i.e. cancer incidence, having a first degree relative with
cancer), Result Type (model 1 only) and psychosocial variables (e.g. uncertainty, spiritual wellbeing) were entered simultaneously as predictors into the model. In the first model with FCP
at T1 as dependent variable, psychosocial variables as assessed at T0 were entered as
predictors. In the second model, the dependent variable was calculated by subtracting the FCP
value at T1 from the FCP value at T2; psychosocial variables as assessed at T1 were entered
as independent variables and for those not assessed at T1, the value at T0 was used. All analyses
were performed in SPSS, version 25.

RESULTS
Data of 721 participants were available for analyses. Participants were mostly female (54.4%)
and middle aged (56 years on average). On average, participants received their first cancer
diagnosis more than 4 years ago (Table 1).

Table 2 summarizes the many trajectories of FCP. High stable (n=52; 7.3%) and low/moderate
stable (n=56; 7.8%) FCP trajectories were typical of the largest groups of participants. No
participant showed high FCP at baseline and subsequent increases from T0 to T1 and from T1
to T2.

Table 3 summarizes the collapsed trajectories per Result Type and the Chi-square statistics.
The trajectories and Result Type were independent. That is, Result Type was not associated
with the development in FCP from T0 to T1 nor from T1 to T2.
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Table 4 summarizes the results of the first multiple linear regression. The regression model
predicting FCP at T1 (model 1) was significant (F(23,376) = 15.14, p <.001) with an R2 of .48.
FCP as assessed at T0 (B = 0.61, t(399) = 14.12, p <.001), FACIT-Sp as assessed at T0 (B = 0.12, t(399) = -2.78, p =.006) and Result Type being ‘Actionable via MoST study’ (B = -1.79,
t(399) = -2.01), p =.045, ‘Not actionable’ as reference category) were the only significant
predictor variables. That is, a higher baseline FCP and a lower baseline level of spiritual
wellbeing predicted higher FCP at T1. Compared to having a non-actionable variant,
individuals with a cancer that was actionable within the MoST study had lower FCP at T1. The
second model was not significant, F(25,259) = 1.05, p =.407 (Supplementary File).

DISCUSSION
This study, the first to explore FCP trajectories in people with advanced cancer receiving
CTGP, showed considerable diversity in trajectories. However, the most common trajectories
were stable, with patients’ FCP staying either high or low over the 5-6 month study period.
Our predictive model of FCP immediately after CTGP results revealed that lower FCP and
higher spiritual wellbeing at baseline, and receiving an actionable result with immediate access
to tailored treatment through a MoST clinical trial, predicted lower FCP post results. However,
no measured variables predicted change in FCP from immediately post results to 2-3 followup (Supplementary file).

Our diverse trajectories are in contrast to results reported by most studies assessing FCR
trajectories, which have defined two to three key trajectories. This difference may be due to
our focus on advanced cancer, where the disease is likely to be more dynamic, with more
frequent scans and symptoms and FCP focused on when, rather than if, progression will occur.
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FCP may be more changeable and responsive to rapid changes in disease symptoms or status.
Nonetheless, our two largest trajectories (each involving 7-8% of the sample) were stable, from
both high and low/moderate baselines, and in our multiple regression, baseline FCP was one
of the few predictors of FCP post-CTGP result. This supports previous findings9,10 which found
high-stable FCR to be common in populations with metastatic disease; not suprising in people
who have been told their cancer is no longer curable.

A second predictor of FCP post-CTGP result was spiritual wellbeing, supporting a recent
study3 showing that death anxiety is a key factor in FCP, while a greater sense of life being
meaningful and purposeful despite cancer, is associated with lower FCP. A sense of meaning
and purpose, and of being at peace with one’s past, current life and relationships and the future,
and faith in a higher being, are all likely to mitigate existential concerns. Spiritual wellbeing is
not commonly assessed in studies addressing FCR in patients with early-stage cancer, but
higher spirituality has been commonly found to be associated with better quality of life in
cancer patients regardless of physical deterioration.34-35

Finally, as predicted, the CTGP result impacted FCP. Importantly it was not just actionability
that influenced FCP, but also the availability of immediate tailored therapy through a clinical
trial associated with the MoST study. Interviews with MoST participants36 indicated that those
who received an actionable result but were told a trial was not available through MoST,
believed that the likelihood of identifying an appropriate trial elsewhere was low, leaving them
without therapy options. MoST was regarded as being led by a highly trusted group of experts,
and therefore participants held little hope of their own oncologists identifying alternative,
suitable trials. Thus their hopes of potentially effective tailored treatment were dashed, leaving
them vulnerable to renewed FCP. Despite some of these participants reporting hope that a
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suitable trial might open in the future,36 this did not seem to be sufficient to reduce FCP, as
there was no difference in FCP between those receiving non-actionable results and actionable
results without a MoST trial.

Our analysis of factors associated with change in FCP from immediately post-CTGP result to
2-3 months follow-up, revealed no significant predictors. Stability post results was the most
common pattern in participants, thus there may have been insufficient variability to detect
predictors. Alternatively, factors that maintain FCP after CTGP results may be different to
those that impact FCP in the immediate aftermath of results. For example, oncologist
communication and support (not measured in the current study), which is known to influence
FCR,37 may be critical in relieving disappointment after receiving a non-actionable result.

Our study had limitations. Our participants were in the MoST study, rather than undergoing
CTGP as part of routine clinical care. Possibly, their FCP motivated participation, and thus
their trajectories, and factors impacting their FCP, may not be the same as those in routine care.
However, these participants were referred to MoST by their oncologists, and there is an
increasingly blurry line between research and clinical practice within genomics, where the
goals of both pursuits, namely best outcomes for patients and generation of new knowledge,
may motivate participation. Thus differences between patients undergoing CTGP in a clinical
versus research setting may not be great.

We had only 2 months follow-up of FCP post results, and may have found more predictors of
change in FCR had we had longer follow-up. However, in this very sick population who had
exhausted treatment options, prognosis was poor, and numbers remaining in the study at
longer follow-up likely very small. A significant proportion of patients had missing data at
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one of the three assessment time points, which meant they could not be included in
trajectories. The PiGeOn study was primarily designed to explore psychological responses to
CTGP testing and result return, rather than predictors of FCP, and measurement of other
factors known to maintain FCP, such as meta-cognitions, were not measured in our study.

Clinical and research implications
People with high FCP and low spiritual wellbeing at baseline appear to be at higher risk of
significantly increased FCP post-CTGP result receipt. Routine screening for these
psychosocial/spiritual characteristics may be helpful in identifying a group of patients who
may benefit from closer monitoring and provision of psychosocial support. Simple tools for
assessing concepts such as spiritual wellbeing are available, that can be incorporated into
routine history taking.38 Repeat screening on result return is likely beneficial, as the type of
result received may also impact FCP. Future studies should explore interventions to best
address FCP in this very vulnerable group, as interventions assessed to date have almost all
addressed curative cancers, or patients newly diagnosed with advanced disease.
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Supplementary file
Table 1:Linear regression analysis predicting the change in Fear of Cancer Regression (FCP) between T1 and T2.
Predictor
(Constant)
FCP at baseline (T0)
Age
Sex: Female (ref) vs. Male
Marital Status: Married (ref) vs. Not married
Having children: No (ref) vs. Yes
Speaking English at home: Yes (ref) vs. No
Medical/Science occupation: No (ref) vs. Yes
Relative with cancer: No (ref) vs. Yes
Education
≤ Secondary (ref) vs. Vocational
≤ Secondary (ref) vs. Undergraduate
≤ Secondary (ref) vs. Postgraduate
Aria
Remote (ref) vs. Major city
Remote (ref) vs. Inner regional
Remote (ref) vs. Outer regional
Cancer incidence
Rare (ref) vs. Common
Rare (ref) vs. Less common
Attitude towards uncertainty (T0)
Knowledge (T0)
FACIT-SP (T1)
Self-efficacy (T0)
Perceived susceptibility (T1)
MICRA (T1)
HHI (T1)
HADS (T1)
IES (T1)

B
11.18
-0.01
-0.0005
-1.55
-0.78
.08
-1.19
-0.88
1.02

SE B
6.32
0.06
.03
0.77
0.97
1.10
1.17
1.52
0.78

β
-.01
-.001
-.12
-.05
.005
-.07
-.04
.08

p-value
.078
.876
.988
.045
.421
.945
.310
.561
.189

0.07
-0.28
-2.53

1.11
1.05
1.11

.004
-.02
-.17

.950
.789
.024

-2.57
-3.65
-4.92

3.20
3.28
3.43

-.19
-.23
-.23

.422
.267
.153

-0.94
-1.35
-0.15
0.02
-0.06
0.05
-0.02
-0.07
-0.05
-0.09
0.02

1.00
1.16
0.81
0.02
0.07
0.69
0.02
0.04
0.13
0.09
0.04

-.06
-.07
-.01
.07
-.09
.01
-.09
-.15
-.04
-.10
.05

.348
.248
.849
.275
.395
.936
.226
.075
.704
.294
.535

1

Note. Aria = Accessibility and Remoteness Index of Australia; FACIT-SP = Functional Assessment of Chronic Illness Therapy - Spiritual Wellbeing; FCP = Fear of Cancer Progression; HADS = Hospital Anxiety and Depression Scale; HHI = Herth Hope Index; IES = Impact of Events
Scale, MICRA = Multidimensional Impact of Cancer Risk Assessment; ref = reference category
The model was not significant, F(25,259) = 1.05, p = .407.

2

Table 1. Sample descriptives
Result Types
Non-actionable
Actionable: Tx via
MoST sub-study

Actionable: Tx via
another pathway

Total

Demographic characteristics
Age, years (mean, SD, range)
Sex, female
Marital status, married
Education
Secondary school or less
Vocational training
Undergraduate university
Postgraduate university
Missing
Medical/Science occupation, no
Having children, yes
Speaking English at home, yes
Accessibility and Remoteness Index of Australia
Major city
Inner regional
Outer regional
Remote
Unknown/overseas
Clinical characteristics
Eastern Cooperative Oncology Group performance status
0
1
2
Missing
Incidence
Common
Less common

55 (14)
18-89
154 (57)
213 (78.9)

56 (14)
20-84
104 (53.9)
144 (74.6)

57 (14)
21-88
134 (51.9)
207 (80.2)

56 (14)
18-89
392 (54.4)
564 (78.2)

106 (39.3)
57 (21.1)
65 (24.1)
41 (15.2)
1 (0.4)
247 (91.5)
217 (80.4)
222 (82.2)

75 (38.9)
29 (15)
62 (32.1)
24 (12.4)
3 (1.6)
181 (93.8)
151 (78.2)
164 (85)

87 (33.7)
47 (18.2)
65 (25.2)
56 (21.7)
3 (1.2)
235 (91.1)
197 (76.4)
216 (83.7)

268 (37.2)
133 (18.4)
192 (26.6)
121 (16.8)
7 (1)
663 (92)
565 (78.4)
602 (83.5)

189 (70)
54 (20)
26 (9.6)
1 (0.4)
0

136 (70.5)
39 (20.2)
14 (7.3)
3 (1.6)
1 (0.5)

181 (70.2)
45 (17.4)
26 (10.1)
6 (2.3)
0

506 (70.2)
138 (19.1)
66 (9.2)
10 (1.4)
1 (0.1)

150 (55.6)
109 (40.4)
10 (3.7)
1 (0.4)

108 (56)
78 (40.4)
5 (2.6)
2 (1.0)

151 (58.5)
100 (38.8)
4 (1.6)
3 (1.2)

409 (56.7)
287 (39.8)
19 (2.6)
6 (0.8)

41 (15.2)
21 (7.8)

32 (16.6)
22 (11.4)

59 (22.9)
34 (13.2)

132 (18.3)
77 (10.7)

Rare
Multiple primary cancers, no
Time since first cancer diagnosis, months (mean, SD, range)
First degree relative with cancer, yes
Fear of Cancer Progression (FCP)
FCP0 (mean, SD, range)
FCP1 (mean, SD, range)
FCP2 (mean, SD, range)

Total

208 (77)
238 (88.1)
47.7 (68)
0-412
146 (54.1)

139 (72)
156 (80.8)
53.6 (76)
0.4-483
85 (44)

165 (64)
216 (83.7)
54.4 (75)
0-504
148 (57.4)

512 (71)
610 (84.6)
51.7 (73)
0-504
379 (52.6)

17.3 (7.7)
0-30
18.2 (7.8)
0.5-30
16 (8.1)
0-30

16.4 (7.9)
0-30
15.2 (8.3)
0-30
14.4 (7.9)
0-30

16.7 (8.4)
0-30
16.2 (8.3)
0-30
15.6 (8.5)
0-30

16.8 (8)
0-30
16.7 (8.2)
0-30
15.4 (8.2)
0-30

270

193

258

721

Note. Unless otherwise indicated, values represent patient numbers (n) and percentages.
Tx = treatment.

Table 2. Trajectories of Fear of Cancer Progression (FCP).
Result Types
Non-actionable
Actionable: Tx via
MoST sub-study

Actionable: Tx via
another pathway

Total

High at baseline, N = 362 (50.5%) a
Stable
Stable - Increase
Stable - Decrease
Decrease - Stable
Decrease - Increase
Decrease - Decrease
Increase - Stable
Increase - Increase
Increase - Decrease
FCP1 or FCP2 missing b
Low/moderate at baseline, N = 355 (49.5%) a
Stable
Stable - Increase
Stable - Decrease
Decrease - Stable
Decrease - Increase
Decrease - Decrease
Increase - Stable
Increase - Increase
Increase - Decrease
FCP1 or FCP2 missing b

20 (7.4)
4 (1.5)
7 (2.6)
9 (3.3)
9 (3.3)
5 (1.9)
5 (1.9)
0
2 (0.7)
83 (30.9)

17 (8.8)
1 (0.5)
6 (3.1)
10 (5.2)
7 (3.6)
4 (2.1)
1 (0.5)
0
5 (2.6)
45 (23.3)

15 (5.9)
3 (1.2)
10 (3.9)
6 (2.4)
8 (3.1)
9 (3.5)
8 (3.1)
0
5 (2.0)
58 (22.7)

52 (7.3)
8 (1.1)
23 (3.2)
25 (3.5)
24 (3.3)
18 (2.5)
14 (2)
0
12 (1.7)
186 (25.9)

19 (7.1)
3 (1.1)
9 (3.3)
7 (2.6)
4 (1.5)
1 (0.4)
13 (4.8)
2 (0.7)
9 (3.3)
58 (21.6)

17 (8.8)
5 (2.6)
9 (4.7)
8 (4.1)
5 (2.6)
0
3 (1.6)
2 (1)
6 (3.1)
42 (21.8)

20 (7.8)
6 (2.4)
9 (3.5)
8 (3.1)
10 (3.9)
1 (0.4)
10 (3.9)
1 (0.4)
10 (3.9)
58 (22.7)

56 (7.8)
14 (2)
27 (3.8)
23 (3.2)
19 (2.6)
2 (0.3)
26 (3.6)
5 (0.7)
25 (3.5)
158 (22)

269 (100)

193 (100)

255 (100)

N = 717 a

Note. Values represent patient numbers (n) and valid percentages within Result Types (%), i.e. percentage of the n=717 cases with a valid FCP0
measure and at least one other valid measure (FCP1 or FCP2).
a
Category at T0 defined by median split based on FCP0 value (Low <18; High: ≥18). Trend in FCP calculated as change score between T0 to T1
and T1 and T2 and then defined by SD of FCP0 (0.5SD=4; decrease ≤-4; stable >-4 and <+4; increase ≥+4). N=4 participants have a missing
value on FCR0, and hence are not classified in the high vs. low/moderate at baseline group. These participants are excluded from this table.
b
Participants with either a missing value on FCP1 or FCP2. Tx = Treatment.

Table 3. Trajectories of Fear of Cancer Progression.
Result Types
Actionable:
Tx via another pathway

Total

Test statisticc

Non-actionable

Actionable:
Tx via MoST sub-study

High-stable/High-increase
High-decrease
Low-stable/Low-decrease
Low-increase
Total

69 (34.3)
37 (18.4)
58 (28.9)
37 (18.4)
201 (100)

42 (28.0)
30 (20)
57 (38.0)
21 (14)
150 (100)

64 (31.4)
31 (15.2)
72 (35.3)
37 (18.1)
204 (100)

175 (31.5)
98 (17.7)
187 (33.7)
95 (17.1)
N = 555

χ2 (6, N=555) =
5.87,
p =.438

(b) Trajectories T1 – T2b
High-stable/High-increase
High-decrease
Low-stable/Low-decrease
Low-increase
Total

46 (35.7)
21 (16.3)
47 (36.4)
15 (11.6)
129 (100)

23 (21.7)
19 (17.9)
47 (44.3)
17 (16)
106 (100)

41 (28.9)
24 (16.9)
53 (37.3)
24 (16.9)
142 (100)

110 (29.2)
64 (17)
147 (39)
56 (14.9)
N = 377

χ2 (6, N=377) =
6.49,
p =.371

(a) Trajectories T0 – T1 a

Note: Values represent patient numbers (n) and valid percentages within Result Types (%), i.e. percentage of the (a) n=555 cases with a valid
FCP0 and FCP1 value and (b) n=377 cases with a valid FCP1 and FCP2 value.
a
Category at T0 defined by median split based on FCP0 value (Low <18; High: ≥18). Trend in FCP calculated as change score between T0 to T1
and then defined by SD of FCR0 (0.5SD=4; decrease ≤-4; stable >-4 and <+4; increase ≥+4). bCategory at T1 defined by median split based on
FCP0 value (Low <18; High: ≥18). Trend in FCP calculated as change score between T1 to T2 and then defined by SD of FCP0 (0.5SD=4;
decrease ≤-4; stable >-4 and <+4; increase ≥+4). Tx = Treatment. cChi-square test.
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Table 4. Linear regression analysis predicting Fear of Cancer Progression (FCP) at T1.
Predictor
(Constant)
FCP at baseline (T0)
Age
Sex: Female (ref) vs. Male
Marital Status: Married (ref) vs. Not married
Having children: No (ref) vs. Yes
Speaking English at home: Yes (ref) vs. No
Medical/Science occupation: No (ref) vs. Yes
Relative with cancer: No (ref) vs. Yes
Result type
Non-actionable (ref) vs. Actionable via MoST
Non-actionable (ref) vs. Actionable other
Education
≤ Secondary (ref) vs. Vocational
≤ Secondary (ref) vs. Undergraduate
≤ Secondary (ref) vs. Postgraduate
Accessibility and Remoteness Index of Australia
Remote (ref) vs. Major city
Remote (ref) vs. Inner regional
Remote (ref) vs. Outer regional
Cancer incidence
Rare (ref) vs. Common
Rare (ref) vs. Less common
Attitude towards uncertainty (T0)
Knowledge (T0)
Functional Assessment of Chronic Illness Therapy - Spiritual Wellbeing
(T0)
Self-efficacy (T0)
Perceived susceptibility (T0)

B
6.98
0.61
-0.02
-0.51
-0.40
0.19
0.54
-0.36
-0.18

SE B
4.44
0.04
0.02
0.64
0.79
0.87
0.89
1.20
0.63

β
.60
-.03
-.03
-.02
.01
.02
-.01
-.01

p-value
.116
< .001
.426
.419
.612
.825
.544
.763
.777

-1.79
-0.85

0.89
0.70

-.08
-.05

.045
.225

-0.07
-0.33
-0.03

0.90
0.86
0.89

-.003
-.02
.002

.939
.705
.972

3.63
2.74
4.83

2.81
2.85
2.93

.21
.13
.18

.196
.338
.100

0.3
1.22
0.51
0.03
-0.12

0.79
0.95
0.67
0.02
0.04

.001
.05
.03
.07
-.12

.970
.199
.448
.084
.006

-0.49
0.01

0.54
0.01

-.04
.03

.361
.544

Note: ref = reference category.
a 2
R = .48; Bold emphasis highlight the statistically significant results.
1

Coefficients for the second model, predicting the change in FCP between T1 and T2, are not depicted here as it was not significant (Supplementary File).
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